Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
974 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,928 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT06109207 | Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas | unknown | Phase 1 | 6 | West China HospitalOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06225921 | Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas | unknown | Phase 1 | 6 | West China HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT02229656 | Olaparib and Radiotherapy in Head and Neck Cancer | unknown | Phase 1 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT05783921 | A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05927844 | XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma | unknown | Phase 1 | 20 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 3, 2023 | clinicaltrials |
| NCT05883007 | Dose Optimized BNCT for Head and Neck Cancer(ST-BNCT2001) | unknown | Phase 1 | 30 | Southern Tohoku BNCT Research CenterOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT03982212 | A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors | unknown | Phase 1 | 10 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05027204 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | unknown | Phase 1 / Phase 2 | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05552807 | SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 | 120 | Sinocelltech Ltd.INDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC(LATE) | unknown | Phase 1 / Phase 2 | 30 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT04213404 | Ribociclib and Spartalizumab in R/M HNSCC(RISE-HN) | unknown | Phase 1 | 13 | National Taiwan University HospitalOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT05317325 | A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT03799744 | Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 | 20 | Institut Català d'OncologiaOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05299203 | BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) | unknown | Phase 1 | 18 | West China HospitalOTHER | 0 | Mar 28, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 46 | Zhejiang Cancer HospitalOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT03843515 | Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction(NeoNivo) | unknown | Phase 1 | 17 | Amsterdam UMC, location VUmcOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT05013268 | Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma(TiTanec) | unknown | Phase 1 | 15 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT03134846 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate(ICON) | unknown | Phase 1 / Phase 2 | 79 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT02054442 | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck(COMMENCE) | unknown | Phase 1 / Phase 2 | 52 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04229537 | Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC | unknown | Phase 1 | 60 | Sinocelltech Ltd.INDUSTRY | 0 | Jan 18, 2020 | clinicaltrials |
| NCT01295502 | Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer | unknown | Phase 1 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03817567 | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 25, 2019 | clinicaltrials |
| NCT02507154 | Reactivating NK Cells in Treating Refractory Head and Neck Cancer(NKEXPHNC) | unknown | Phase 1 / Phase 2 | 31 | National University Hospital, SingaporeOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | unknown | Phase 1 | 69 | Threshold PharmaceuticalsINDUSTRY | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02876978 | Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | unknown | Phase 1 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT01993784 | Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma. | unknown | Phase 1 / Phase 2 | 9 | Peking UniversityOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01760811 | CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT | unknown | Phase 1 / Phase 2 | 25 | Rabin Medical CenterOTHER | 1 | Jan 4, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Dec 18, 2024source: clinicaltrials